3933 (3933) Fair Value & Analysis

Healthcare · Market cap HK$18.2B

3 3933 3933 · HK

PriceHK$9.26

Fair ValueHK$25.81

Upside+178.7%

Quality41/100

Watch 3933 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$16.25 – HK$31.47

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price +2.1% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$8.06 – HK$17.58 · fair‑value band HK$16.25 – HK$31.47 · the HK$9.26 price screens below the HK$25.81 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

3933 (3933) currently trades at HK$9.26, while our model-based Fair Value estimate is HK$25.81 — implying the stock looks roughly 178.7% undervalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 3933 generated revenue of HK$13.2B at a net margin of 15.8%. Revenue declined 13.5% year over year. It earns a return on equity of 13.0%. The balance sheet holds a net cash position of HK$6.2B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$13.2B

Revenue growth (YoY) -13.5%

Net margin 15.8%

Return on equity 13.0%

Free cash flow HK$855M FY2025

P/E ratio 7.2

More key figures

Operating margin -0.5%

EPS (TTM) HK$1.04

Dividend yield 5.0%

EPS growth (YoY) -84.7%

Net cash HK$6.2B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3933 reported revenue of HK$13.2B in FY2025 versus HK$9.7B in FY2021, a compound +8.0%/yr. Reported net income was HK$2.1B in FY2025, compounding +20.5%/yr from FY2021.

Revenue +8.0%/yr

FY21 HK$9.7B

FY22 HK$11.3B

FY23 HK$13.7B

FY24 HK$13.8B

FY25 HK$13.2B

Net income +20.5%/yr

FY21 HK$988M

FY22 HK$1.6B

FY23 HK$2.7B

FY24 HK$2.7B

FY25 HK$2.1B

Is 3933 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥49.36	¥26.59	-46%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,782	₹915.92	-49%
Zoetis Inc Z1TS34	R$26.19	R$26.01	-1%
Hansoh Pharmaceutical Group 3692	HK$29.58	HK$18.75	-37%
Divi's Laboratories Limited DIVISLAB	₹6,788	₹2,035	-70%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 3933 (3933) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$25.81 versus a price of HK$9.26 — about +179% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 3933?

Our model-based fair value for 3933 is HK$25.81 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$9.26.

What is the quality score of 3933?

3933 has a Quality Score of 41/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 3933 (3933)?

3933 reported trailing-twelve-month revenue of about HK$13.2B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 3933?

The net profit margin of 3933 is about 15.8%, meaning it keeps roughly 15.8% of revenue as net income. Based on the latest reported figures.

Does 3933 pay a dividend?

3933 currently shows a dividend yield of about 4.98% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.